A Phase 2 Trial Testing ZP1848 in Patients With SBS

Trial Profile

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Glepaglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 19 Jun 2017 Results published in a Zealand Pharma media release.
    • 19 Jun 2017 Primary endpoint (wet weight of ostomy output or diarrhea) has been met according to a Zealand Pharma media release.
    • 17 May 2017 According to a Zealand Pharma media release, results are expected by end June 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top